A substantial number of patients did not attain optimal estrogen suppression with the gonadotropin-releasing hormone agonist triptorelin.
The prior combined analysis of the SOFT and TEXT trials (N Engl J Med 2014; 371:107) showed that disease-free survival was improved with the aromatase inhibitor (AI) exemestane plus ovarian function suppression (OFS) versus tamoxifen plus OFS in premenopausal women with hormone-receptor-positive breast cancer. Now, investigators have conducted a prospective study of patients in the SOFT trial to determine what percentage of those receiving exemestane plus OFS with the gonadotropin-releasing hormone (GnRH) agonist triptorelin experienced suboptimal estrogen suppression.
Patients provided blood samples at 0, 3, 6, 12, 18, 24, 36, and 48 months for analysis of estradiol, estrone, estrone sulfate, follicle-stimulating hormone (FSH), and luteiniz…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)